Dimerix Ltd

DXB

Company Profile

  • Business description

    Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD, as well as the proprietary ReceptorHIT assay technology. It pursues new product concepts and applies deep scientific knowledge to the discovery of products from early-stage development through to commercialisation. Dimerix products will target multiple territories. The Group has only operated in one Segment, being investment in research and development of biopharmaceutical drugs.

  • Contact

    425 Smith Street
    FitzroyVIC3065
    AUS

    T: +61 1300813321

    https://www.dimerix.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    9

Stocks News & Analysis

stocks

Solid start to fiscal 2026 for BHP

Production guidance is maintained by management.
stocks

Coca-Cola earnings: Innovation and brand strength underpin growth

We plan to raise our fair value estimate of Coca-Cola stock.
stocks

Going into earnings, is Netflix stock a buy, a sell, or fairly valued?

Watching sales growth and the potential for margin expansion, here’s what we think of Netflix stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,321.1010.80-0.12%
CAC 408,218.3440.52-0.49%
DAX 4024,250.0879.95-0.33%
Dow JONES (US)46,805.29119.45-0.25%
FTSE 1009,533.18106.191.13%
HKSE25,781.77245.78-0.94%
NASDAQ22,931.8721.79-0.09%
Nikkei 22549,307.798.27-0.02%
NZX 50 Index13,306.4471.41-0.53%
S&P 5006,733.322.03-0.03%
S&P/ASX 2009,030.0010.30-0.11%
SSE Composite Index3,913.762.57-0.07%

Market Movers